Trial Results Demonstrate Diagnostic Performance of Aurora Dedicated Breast MRI System Over Whole-Body Breast MRI

October 2, 2012 — A clinical trial published in the October issue of Radiology demonstrates that Aurora Imaging Technology’s 1.5T dedicated breast MRI (magnetic resonance imaging) system led to better diagnostic performance for all metrics (sensitivity, specificity, negative predictive value [NPV], positive predictive value [PPV] and receiver operating characteristic [ROC] area) than has been historically reported in trials for breast MRI on whole-body MRI scanners. In addition, the low frequency of false positive and false negative findings associated with the dedicated breast MRI system allows for use of breast MRI with low risk of patient harm in both the screening and diagnostic environments. The study was managed by ACR Image Metrix, the American College of Radiology’s clinical research organization.

“The results of this multicenter trial validate what we have suspected for many years, which is, using a dedicated MRI system optimized for breast imaging results in superior diagnostic performance. In addition, we were able to demonstrate consistency of performance across a variety of breast imaging centers, university, community hospital and independent breast centers,” said Steven Harms, M.D., primary investigator for the study.

The study included more than 900 patients and resulted in sensitivity and specificity for the dedicated breast MRI system of 92 percent (92/100) and 88.9 percent (741/834), respectively. For all cases, the NPV was 98.9 percent (741/749), and the NPV for screening cases was 100 percent (326/326). The area under the ROC curve was 94.2 percent. The false positive rate was 93/834 (11 percent) for all cases, but only 16/326 (4.7 percent) for the screening cohort.

Alan Hollingsworth, M.D., medical director, breast surgeon at Mercy Women’s Center at Mercy Health Center, and study investigator added, “False positive rates from previously reported trials using whole-body breast MRI have typically been between 30-50 percent. These studies have led to criticism of breast MRI for its high false positive rates, resulting in unnecessary biopsies, surgical procedures and anxiety for the patient. The dedicated breast MRI system offers a significant improvement in performance. Even within the 93 false positives, 25 (27 percent) were high-risk histologies for which excision is often recommended. This kind of performance should provide breast radiologists and surgeons alike a higher level of diagnostic confidence, and could have significant impact on the role of breast MRI”.

For more information: www.auroramri.com


Related Content

News | Computed Tomography (CT)

SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...

Time August 06, 2024
arrow
News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
Feature | Computed Tomography (CT) | By Melinda Taschetta-Millane

In the ever-evolving landscape of medical imaging, computed tomography (CT) stands out as a cornerstone technology ...

Time July 30, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
News | Breast Imaging

July 29, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the ...

Time July 29, 2024
arrow
News | Breast Imaging

July 29, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced a ...

Time July 29, 2024
arrow
Feature | Radiology Business | By Christine Book

Across the healthcare industry, and, notably, throughout the radiology community in just the past few years, the focus ...

Time July 26, 2024
arrow
Feature | Mobile C-Arms | By Melinda Taschetta-Millane

Mobile C-arms continue to revolutionize medical imaging, offering versatility, mobility and real-time visualization ...

Time July 26, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiology Business

July 25, 2024 — The radiology gender gap is decreasing, but there remains work to be done, according to an editorial ...

Time July 25, 2024
arrow
Subscribe Now